Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows

Share :
Published: 19 Jun 2014
Views: 2932
Prof Peter Hillmen - St James’ University Hospital, Leeds, UK

At a press conference at EHA 2014, Prof Hillmen presented the results of a multicentre, international, phase 3 study (RESONATE) which assessed daily ibrutinib monotherapy versus the anti-CD20 antibody ofatumumab and found that ibrutinib significantly improved overall survival.

See the article for more.